N. E. Kemeny

672 total citations
24 papers, 521 citations indexed

About

N. E. Kemeny is a scholar working on Oncology, Hepatology and Surgery. According to data from OpenAlex, N. E. Kemeny has authored 24 papers receiving a total of 521 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Hepatology and 8 papers in Surgery. Recurrent topics in N. E. Kemeny's work include Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Colorectal Cancer Treatments and Studies (8 papers) and Cancer Treatment and Pharmacology (5 papers). N. E. Kemeny is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Colorectal Cancer Treatments and Studies (8 papers) and Cancer Treatment and Pharmacology (5 papers). N. E. Kemeny collaborates with scholars based in United States and Switzerland. N. E. Kemeny's co-authors include Leonard B. Saltz, A. M. Cohen, David P. Kelsen, Joanne Frankel, Elin R. Sigurdson, Bruce D. Minsky, Warren E. Enker, Bonnie Reichman, Heinz‐Josef Lenz and Scott Wadler and has published in prestigious journals such as Journal of Clinical Oncology, Blood and European Journal of Cancer.

In The Last Decade

N. E. Kemeny

23 papers receiving 506 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
N. E. Kemeny United States 10 406 221 131 116 83 24 521
Robert Goslin United States 5 306 0.8× 126 0.6× 111 0.8× 126 1.1× 66 0.8× 5 411
Theo Ruers Netherlands 10 460 1.1× 189 0.9× 153 1.2× 372 3.2× 26 0.3× 13 606
Wendy Langeberg United States 2 354 0.9× 172 0.8× 114 0.9× 318 2.7× 23 0.3× 3 496
Julien Leporrier France 3 331 0.8× 181 0.8× 98 0.7× 326 2.8× 25 0.3× 3 439
Kazumi Itoi Japan 9 240 0.6× 122 0.6× 252 1.9× 148 1.3× 50 0.6× 22 421
Nicolas Moosmann Germany 12 449 1.1× 84 0.4× 216 1.6× 107 0.9× 45 0.5× 39 512
Chi‐Chung Tong China 13 271 0.7× 230 1.0× 136 1.0× 34 0.3× 76 0.9× 31 590
Massimo Tilli Italy 8 341 0.8× 269 1.2× 221 1.7× 459 4.0× 32 0.4× 18 604
Won Kyung Cho South Korea 12 207 0.5× 135 0.6× 165 1.3× 44 0.4× 72 0.9× 56 462
Beata Herberger Austria 13 516 1.3× 337 1.5× 224 1.7× 398 3.4× 119 1.4× 19 810

Countries citing papers authored by N. E. Kemeny

Since Specialization
Citations

This map shows the geographic impact of N. E. Kemeny's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. E. Kemeny with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. E. Kemeny more than expected).

Fields of papers citing papers by N. E. Kemeny

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. E. Kemeny. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. E. Kemeny. The network helps show where N. E. Kemeny may publish in the future.

Co-authorship network of co-authors of N. E. Kemeny

This figure shows the co-authorship network connecting the top 25 collaborators of N. E. Kemeny. A scholar is included among the top collaborators of N. E. Kemeny based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. E. Kemeny. N. E. Kemeny is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wanebo, Harold J., Mark LeGolvan, Philip B. Paty, et al.. (2012). Meeting the biologic challenge of colorectal metastases. Clinical & Experimental Metastasis. 29(7). 821–839. 40 indexed citations
2.
Kemeny, N. E., Mithat Gönen, Michael I. D’Angelica, et al.. (2011). Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: Does the addition of systemic bevacizumab improve results?. Journal of Clinical Oncology. 29(15_suppl). e14658–e14658. 1 indexed citations
3.
Ma, Jingfei, Marinela Capanu, Eileen M. O’Reilly, et al.. (2011). Does the underlying etiology of HCC effect outcome? A single-institution analysis.. Journal of Clinical Oncology. 29(15_suppl). e14636–e14636.
4.
Kemeny, N. E., David H. Gültekin, Zubin M. Bamboat, et al.. (2010). Dynamic contrast enhanced MRI (DCE-MRI) to measure antiangiogenic therapy and predict treatment response in primary liver cancer (PLC).. Journal of Clinical Oncology. 28(15_suppl). e14537–e14537. 1 indexed citations
5.
Power, Derek G., Marinela Capanu, Dina Patel, et al.. (2010). Unexpected increased biliary toxicity when systemic bevacizumab is added to hepatic arterial infusion.. Journal of Clinical Oncology. 28(15_suppl). 3559–3559. 9 indexed citations
6.
Kemeny, N. E., Marinela Capanu, Yuman Fong, et al.. (2008). Survival after resection of liver metastases from colorectal cancer with poor clinical risk factors using adjuvant systemic plus hepatic arterial therapy. Journal of Clinical Oncology. 26(15_suppl). 4076–4076. 4 indexed citations
7.
Chung, Kwanghun & N. E. Kemeny. (2005). Regional and Systemic Chemotherapy for Primary Hepatobiliary Cancers and for Colorectal Cancer Metastatic to the Liver. Seminars in Radiation Oncology. 15(4). 284–298. 12 indexed citations
8.
Romanus, Dorothy, et al.. (2005). PCN13 COST-EFFECTIVENESS OF HEPATIC ARTERY INFUSION FOR METASTATIC COLORECTAL CANCER (CALGB 9481). Value in Health. 8(6). A37–A37. 2 indexed citations
9.
Daghighian, Farhad, John L. Humm, Homer A. Macapinlac, et al.. (1996). Pharmacokinetics and dosimetry of iodine-125-IUdR in the treatment of colorectal cancer metastatic to liver.. PubMed. 37(4 Suppl). 29S–32S. 12 indexed citations
10.
Cohen, A. M. & N. E. Kemeny. (1996). Is intra-arterial chemotherapy worthwhile in the treatment of patients with unresectable hepatic colorectal cancer metastases?. European Journal of Cancer. 32(13). 2195–2197. 22 indexed citations
11.
Macapinlac, Homer A., N. E. Kemeny, Farhad Daghighian, et al.. (1996). Pilot clinical trial of 5-[125I]iodo-2'-deoxyuridine in the treatment of colorectal cancer metastatic to the liver.. PubMed. 37(4 Suppl). 25S–29S. 25 indexed citations
12.
Minsky, Bruce D., A. M. Cohen, N. E. Kemeny, et al.. (1992). Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach.. Journal of Clinical Oncology. 10(8). 1218–1224. 172 indexed citations
13.
Kemeny, N. E., et al.. (1992). Overview of N-(phosphonacetyl)-L-aspartate + fluorouracil in clinical trials.. PubMed. 19(2 Suppl 3). 228–33. 4 indexed citations
14.
Kemeny, N. E., et al.. (1992). Modulation of fluorouracil by N-(phosphonacetyl)-L-asparate: a review.. PubMed. 19(2 Suppl 3). 49–55. 8 indexed citations
15.
16.
Daly, Jeanette M. & N. E. Kemeny. (1986). Therapy of colorectal hepatic metastases.. PubMed. 251–68. 9 indexed citations
17.
Kemeny, N. E., et al.. (1984). Phase II trial of 4-demethoxydaunorubicin in advanced colorectal carcinoma.. PubMed. 68(4). 689–90. 8 indexed citations
18.
Kemeny, N. E., et al.. (1984). Phase II evaluation of metoprine in advanced pancreatic adenocarcinoma.. PubMed. 68(7-8). 1053–4. 1 indexed citations
19.
Ahmed, Tamjeed, et al.. (1983). Phase II trial of bisantrene in advanced colorectal carcinoma.. PubMed. 67(3). 307–8. 1 indexed citations
20.
Michaelson, Richard A., N. E. Kemeny, & Charles W. Young. (1982). Phase II evaluation of 4'-epi-doxorubicin in patients with advanced colorectal carcinoma.. PubMed. 66(9). 1757–8. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert Goslin Breakdown of academic impact, for papers by Theo Ruers Breakdown of academic impact, for papers by Wendy Langeberg Breakdown of academic impact, for papers by Julien Leporrier Breakdown of academic impact, for papers by Kazumi Itoi Breakdown of academic impact, for papers by Nicolas Moosmann Breakdown of academic impact, for papers by Chi‐Chung Tong Breakdown of academic impact, for papers by Massimo Tilli Breakdown of academic impact, for papers by Won Kyung Cho Breakdown of academic impact, for papers by Beata Herberger
Rankless by CCL
2026